Structure-Based Identification of Inhibitory Fragments Targeting the p300/CBP-Associated Factor Bromodomain

Journal of Medicinal Chemistry

Volumn 59, Issue 4, 2016, Pages 1648-1653

  Chaikuad, Apirat ^a   Lang, Steffen ^e   Brennan, Paul E ^a   Temperini, Claudia ^c   Fedorov, Oleg ^a   Hollander, Johan ^d   Nachane, Ruta ^d   Abell, Chris ^e   Müller, Susanne ^a   Siegal, Gregg ^d   Knapp, Stefan ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b GOETHE UNIVERSITY   (Germany)

^c LEIDEN UNIVERSITY   (Netherlands)

^d ZoBio   (Netherlands)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; BROMODOMAIN INHIBITOR; E1A ASSOCIATED P300 PROTEIN; LIGAND; LYSINE DERIVATIVE; HISTONE ACETYLTRANSFERASE PCAF; MOLECULAR LIBRARY; P300-CBP-ASSOCIATED FACTOR; PROTEIN BINDING;

ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; METABOLISM; MOLECULAR DOCKING; MOLECULAR LIBRARY; MOLECULAR MODEL; PHARMACOLOGY; PROTEIN TERTIARY STRUCTURE;

DRUG DISCOVERY; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; P300-CBP TRANSCRIPTION FACTORS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SMALL MOLECULE LIBRARIES;

EID: 84959449985     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01719     Document Type: Article

References (31)

1. Filippakopoulos, P.; Knapp, S. Targeting bromodomains: epigenetic readers of lysine acetylation Nat. Rev. Drug Discovery 2014, 13, 337-356 10.1038/nrd4286
2. Muller, S.; Filippakopoulos, P.; Knapp, S. Bromodomains as therapeutic targets Expert Rev. Mol. Med. 2011, 13, e29 10.1017/S1462399411001992
3. Vidler, L. R.; Brown, N.; Knapp, S.; Hoelder, S. Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites J. Med. Chem. 2012, 55, 7346-7359 10.1021/jm300346w
4. Drouin, L.; McGrath, S.; Vidler, L. R.; Chaikuad, A.; Monteiro, O.; Tallant, C.; Philpott, M.; Rogers, C.; Fedorov, O.; Liu, M.; Akhtar, W.; Hayes, A.; Raynaud, F.; Muller, S.; Knapp, S.; Hoelder, S. Structure enabled design of BAZ2-ICR, a chemical probe targeting the bromodomains of BAZ2A and BAZ2B J. Med. Chem. 2015, 58, 2553-2559 10.1021/jm501963e
5. Chen, P.; Chaikuad, A.; Bamborough, P.; Bantscheff, M.; Bountra, C.; Chung, C. W.; Fedorov, O.; Grandi, P.; Jung, D.; Lesniak, R.; Lindon, M.; Muller, S.; Philpott, M.; Prinjha, R.; Rogers, C.; Selenski, C.; Tallant, C.; Werner, T.; Willson, T. M.; Knapp, S.; Drewry, D. H. Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B J. Med. Chem. 2016, 10.1021/acs.jmedchem.5b00209
6. Bamborough, P.; Chung, C. W.; Furze, R. C.; Grandi, P.; Michon, A. M.; Sheppard, R. J.; Barnett, H.; Diallo, H.; Dixon, D. P.; Douault, C.; Jones, E. J.; Karamshi, B.; Mitchell, D. J.; Prinjha, R. K.; Rau, C.; Watson, R. J.; Werner, T.; Demont, E. H. Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors J. Med. Chem. 2015, 58, 6151 10.1021/acs.jmedchem.5b00773
7. Bennett, J.; Fedorov, O.; Tallant, C.; Monteiro, O.; Meier, J.; Gamble, V.; Savitsky, P.; Nunez-Alonso, G. A.; Haendler, B.; Rogers, C.; Brennan, P. E.; Muller, S.; Knapp, S. Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF. J. Med. Chem. 2016, 10.1021/acs.jmedchem.5b00458.
8. Demont, E. H.; Chung, C. W.; Furze, R. C.; Grandi, P.; Michon, A. M.; Wellaway, C.; Barrett, N.; Bridges, A. M.; Craggs, P. D.; Diallo, H.; Dixon, D. P.; Douault, C.; Emmons, A. J.; Jones, E. J.; Karamshi, B. V.; Locke, K.; Mitchell, D. J.; Mouzon, B. H.; Prinjha, R. K.; Roberts, A. D.; Sheppard, R. J.; Watson, R. J.; Bamborough, P. Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain Inhibitors J. Med. Chem. 2015, 58, 5649-5673 10.1021/acs.jmedchem.5b00772
9. Hay, D. A.; Fedorov, O.; Martin, S.; Singleton, D. C.; Tallant, C.; Wells, C.; Picaud, S.; Philpott, M.; Monteiro, O. P.; Rogers, C. M.; Conway, S. J.; Rooney, T. P.; Tumber, A.; Yapp, C.; Filippakopoulos, P.; Bunnage, M. E.; Muller, S.; Knapp, S.; Schofield, C. J.; Brennan, P. E. Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains J. Am. Chem. Soc. 2014, 136, 9308-9319 10.1021/ja412434f
10. Clark, P. G.; Vieira, L. C.; Tallant, C.; Fedorov, O.; Singleton, D. C.; Rogers, C. M.; Monteiro, O. P.; Bennett, J. M.; Baronio, R.; Muller, S.; Daniels, D. L.; Mendez, J.; Knapp, S.; Brennan, P. E.; Dixon, D. J. LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor Angew. Chem., Int. Ed. 2015, 54, 6217-6221 10.1002/anie.201501394
11. Chaikuad, A.; Petros, A. M.; Fedorov, O.; Xu, J.; Knapp, S. Structure-based approaches towards identification of fragments for the low-druggability ATAD2 bromodomain MedChemComm 2014, 5, 1843-1848 10.1039/C4MD00237G
12. Ferguson, F. M.; Fedorov, O.; Chaikuad, A.; Philpott, M.; Muniz, J. R.; Felletar, I.; von Delft, F.; Heightman, T.; Knapp, S.; Abell, C.; Ciulli, A. Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain J. Med. Chem. 2013, 56, 10183-10187 10.1021/jm401582c
13. Bannister, A. J.; Kouzarides, T. The CBP co-activator is a histone acetyltransferase Nature 1996, 384, 641-643 10.1038/384641a0
14. Ogryzko, V. V.; Schiltz, R. L.; Russanova, V.; Howard, B. H.; Nakatani, Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases Cell 1996, 87, 953-959 10.1016/S0092-8674(00)82001-2
15. Yang, X. J.; Ogryzko, V. V.; Nishikawa, J.; Howard, B. H.; Nakatani, Y. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A Nature 1996, 382, 319-324 10.1038/382319a0
16. Linares, L. K.; Kiernan, R.; Triboulet, R.; Chable-Bessia, C.; Latreille, D.; Cuvier, O.; Lacroix, M.; Le Cam, L.; Coux, O.; Benkirane, M. Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2 Nat. Cell Biol. 2007, 9, 331-338 10.1038/ncb1545
17. Lau, O. D.; Courtney, A. D.; Vassilev, A.; Marzilli, L. A.; Cotter, R. J.; Nakatani, Y.; Cole, P. A. p300/CBP-associated factor histone acetyltransferase processing of a peptide substrate. Kinetic analysis of the catalytic mechanism J. Biol. Chem. 2000, 275, 21953-21959 10.1074/jbc.M003219200
18. Lau, O. D.; Kundu, T. K.; Soccio, R. E.; Ait-Si-Ali, S.; Khalil, E. M.; Vassilev, A.; Wolffe, A. P.; Nakatani, Y.; Roeder, R. G.; Cole, P. A. HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF Mol. Cell 2000, 5, 589-595 10.1016/S1097-2765(00)80452-9
19. Mujtaba, S.; He, Y.; Zeng, L.; Farooq, A.; Carlson, J. E.; Ott, M.; Verdin, E.; Zhou, M. M. Structural basis of lysine-acetylated HIV-1 Tat recognition by PCAF bromodomain Mol. Cell 2002, 9, 575-586 10.1016/S1097-2765(02)00483-5
20. Dorr, A.; Kiermer, V.; Pedal, A.; Rackwitz, H. R.; Henklein, P.; Schubert, U.; Zhou, M. M.; Verdin, E.; Ott, M. Transcriptional synergy between Tat and PCAF is dependent on the binding of acetylated Tat to the PCAF bromodomain EMBO J. 2002, 21, 2715-2723 10.1093/emboj/21.11.2715
21. Zeng, L.; Li, J.; Muller, M.; Yan, S.; Mujtaba, S.; Pan, C.; Wang, Z.; Zhou, M. M. Selective small molecules blocking HIV-1 Tat and coactivator PCAF association J. Am. Chem. Soc. 2005, 127, 2376-2377 10.1021/ja044885g
22. Hu, P.; Wang, X.; Zhang, B.; Zhang, S.; Wang, Q.; Wang, Z. Fluorescence polarization for the evaluation of small-molecule inhibitors of PCAF BRD/Tat-AcK50 association ChemMedChem 2014, 9, 928-931 10.1002/cmdc.201300499
23. Filippakopoulos, P.; Picaud, S.; Mangos, M.; Keates, T.; Lambert, J. P.; Barsyte-Lovejoy, D.; Felletar, I.; Volkmer, R.; Muller, S.; Pawson, T.; Gingras, A. C.; Arrowsmith, C. H.; Knapp, S. Histone recognition and large-scale structural analysis of the human bromodomain family Cell 2012, 149, 214-231 10.1016/j.cell.2012.02.013
24. Vanwetswinkel, S.; Heetebrij, R. J.; van Duynhoven, J.; Hollander, J. G.; Filippov, D. V.; Hajduk, P. J.; Siegal, G. TINS, target immobilized NMR screening: an efficient and sensitive method for ligand discovery Chem. Biol. 2005, 12, 207-216 10.1016/j.chembiol.2004.12.004
25. Hewings, D. S.; Fedorov, O.; Filippakopoulos, P.; Martin, S.; Picaud, S.; Tumber, A.; Wells, C.; Olcina, M. M.; Freeman, K.; Gill, A.; Ritchie, A. J.; Sheppard, D. W.; Russell, A. J.; Hammond, E. M.; Knapp, S.; Brennan, P. E.; Conway, S. J. Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands J. Med. Chem. 2013, 56, 3217-3227 10.1021/jm301588r
26. Fedorov, O.; Niesen, F. H.; Knapp, S. Kinase inhibitor selectivity profiling using differential scanning fluorimetry Methods Mol. Biol. 2012, 795, 109-118 10.1007/978-1-61779-337-0-7
27. Chaikuad, A.; Knapp, S.; von Delft, F. Defined PEG smears as an alternative approach to enhance the search for crystallization conditions and crystal-quality improvement in reduced screens Acta Crystallogr., Sect. D: Biol. Crystallogr. 2015, 71, 1627-1639 10.1107/S1399004715007968
28. McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J. Phaser crystallographic software J. Appl. Crystallogr. 2007, 40, 658-674 10.1107/S0021889807021206
29. Winn, M. D.; Ballard, C. C.; Cowtan, K. D.; Dodson, E. J.; Emsley, P.; Evans, P. R.; Keegan, R. M.; Krissinel, E. B.; Leslie, A. G.; McCoy, A.; McNicholas, S. J.; Murshudov, G. N.; Pannu, N. S.; Potterton, E. A.; Powell, H. R.; Read, R. J.; Vagin, A.; Wilson, K. S. Overview of the CCP4 suite and current developments Acta Crystallogr., Sect. D: Biol. Crystallogr. 2011, 67, 235-242 10.1107/S0907444910045749
30. Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and development of Coot Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 486-501 10.1107/S0907444910007493
31. Skubak, P.; Murshudov, G. N.; Pannu, N. S. Direct incorporation of experimental phase information in model refinement Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2196-2201 10.1107/S0907444904019079